| Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT ML Sorror, MB Maris, R Storb, F Baron, BM Sandmaier, DG Maloney, ... Blood 106 (8), 2912-2919, 2005 | 2994 | 2005 |
| Comorbidity and disease status–based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell … ML Sorror, BM Sandmaier, BE Storer, MB Maris, F Baron, DG Maloney, ... Journal of Clinical Oncology 25 (27), 4246-4254, 2007 | 476 | 2007 |
| Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood … M Mohty, F Malard, M Abecassis, E Aerts, AS Alaskar, M Aljurf, M Arat, ... Bone marrow transplantation 51 (7), 906-912, 2016 | 446 | 2016 |
| Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning F Baron, MB Maris, BM Sandmaier, BE Storer, M Sorror, R Diaconescu, ... Journal of clinical oncology 23 (9), 1993-2003, 2005 | 433 | 2005 |
| Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation … M Mohty, F Malard, M Abecassis, E Aerts, AS Alaskar, M Aljurf, M Arat, ... Bone marrow transplantation 50 (6), 781-789, 2015 | 401 | 2015 |
| Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized … S Amadori, S Suciu, D Selleslag, F Aversa, G Gaidano, M Musso, ... Journal of Clinical Oncology 34 (9), 972-979, 2016 | 372 | 2016 |
| Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning F Baron, JE Baker, R Storb, TA Gooley, BM Sandmaier, MB Maris, ... Blood 104 (8), 2254-2262, 2004 | 321 | 2004 |
| Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched … F Baron, C Lechanteur, E Willems, F Bruck, E Baudoux, L Seidel, ... Biology of blood and marrow transplantation 16 (6), 838-847, 2010 | 283 | 2010 |
| Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States L Muffly, MC Pasquini, M Martens, R Brazauskas, X Zhu, K Adekola, ... Blood, The Journal of the American Society of Hematology 130 (9), 1156-1164, 2017 | 258 | 2017 |
| Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia … F Baron, M Labopin, D Niederwieser, S Vigouroux, JJ Cornelissen, ... Leukemia 26 (12), 2462-2468, 2012 | 235 | 2012 |
| Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT P Tsirigotis, M Byrne, C Schmid, F Baron, F Ciceri, J Esteve, NC Gorin, ... Bone marrow transplantation 51 (11), 1431-1438, 2016 | 230 | 2016 |
| Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning F Baron, BM Sandmaier Leukemia 20 (10), 1690-1700, 2006 | 199 | 2006 |
| Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute … S Giebel, A Czyz, O Ottmann, F Baron, E Brissot, F Ciceri, JJ Cornelissen, ... Cancer 122 (19), 2941-2951, 2016 | 173 | 2016 |
| Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo J Cuende, S Liénart, O Dedobbeleer, B van der Woning, G De Boeck, ... Science translational medicine 7 (284), 284ra56-284ra56, 2015 | 166 | 2015 |
| Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and … R Shouval, M Labopin, O Bondi, H Mishan-Shamay, A Shimoni, F Ciceri, ... Journal of Clinical Oncology 33 (28), 3144-3151, 2015 | 152 | 2015 |
| Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia … F Baron, M Mohty, D Blaise, G Socié, M Labopin, J Esteve, F Ciceri, ... Haematologica 102 (2), 224, 2017 | 138 | 2017 |
| Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European … S Giebel, DI Marks, N Boissel, F Baron, S Chiaretti, F Ciceri, ... Bone marrow transplantation 54 (6), 798-809, 2019 | 135 | 2019 |
| Mesenchymal stromal cells: a new tool against graft-versus-host disease? F Baron, R Storb Biology of Blood and Marrow Transplantation 18 (6), 822-840, 2012 | 131 | 2012 |
| Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I–II, open-label, clinical study O Detry, M Vandermeulen, MH Delbouille, J Somja, N Bletard, A Briquet, ... Journal of Hepatology 67 (1), 47-55, 2017 | 126 | 2017 |
| Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from … A Bazarbachi, G Bug, F Baron, E Brissot, F Ciceri, I Abou Dalle, H Döhner, ... haematologica 105 (6), 1507, 2020 | 125 | 2020 |
